



Invited Lecture Series

Topic: Azanucleoside Drugs

The Prague Azanucleoside Drugs and the Beginnings of Epigenetic Therapy

The nucleoside analogs, 5-azacytidine and 5-aza-2'-deoxycytidine, were synthesized in the IOCB. Recent excitement with these chemicals has been engendered by the approval for their use in myeloid dysplastic syndrome by the United States Food and Drug Administration. We call this therapy "epigenetic therapy" because of the ability of the drugs to activate genes which have become inappropriately silenced during cancer formation. The synthesis of the azanucleotides in the 1960s has therefore had great impact in our understanding of epigenetic processes, in gene discovery and now in patient treatment.

Speaker: Professor Peter A. Jones

Norris Comprehensive Cancer Center,
University of Southern California, Los Angeles, USA

ÚOCHB AV ČR

Ústav organické chemie a biochemie AV ČR
Flemingovo nám. 2, Praha 6

Lecture Hall 10:00 am